Subscribe
360b-shutterstock-com-9
360b / Shutterstock.com
22 July 2015Americas

Federal Circuit says ‘patent dance’ is optional

The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
Americas
Federal Circuit denies rehearing in ‘patent dance’ case
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
Americas
Federal Circuit denies rehearing in ‘patent dance’ case
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.

More on this story

Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
Americas
Federal Circuit denies rehearing in ‘patent dance’ case
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility